BiotechTube
TargImmune Therapeutics

TargImmune Therapeutics

Basel, Switzerland· Est.
targimmune.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

TargImmune Therapeutics is a private, pre-clinical stage biotech developing a first-in-class targeted nucleic acid delivery platform known as Targeted Apoptosis and Immune Modulators (TAIMs). The platform utilizes synthetic nanoparticles to deliver interchangeable nucleic acid payloads, such as double-stranded RNA (dsRNA), directly to tumors, inducing both cancer cell death and immune modulation. The lead program, TAR001, targets EGFR-overexpressing cancers and is on track for an IND/CTA filing in the first half of 2024, with the platform holding potential for application beyond oncology.

Oncology

Technology Platform

Proprietary synthetic nanoparticle platform for systemic, targeted delivery of interchangeable nucleic acid therapeutics (TAIMs - Targeted Apoptosis and Immune Modulators). Initial payload is dsRNA, designed to mimic viral infection to induce cancer cell apoptosis and immune modulation.

Funding History

1
Total raised:$20M
Series A$20M

Opportunities

The platform addresses key unmet needs in oncology, including treating metastatic disease and 'cold' tumors, by combining direct cell killing with immune activation.
Its modular nature offers potential expansion beyond dsRNA to other nucleic acid payloads and into therapeutic areas beyond oncology.

Risk Factors

High technical risk associated with first-in-human testing of a novel platform and dsRNA payload, with potential for off-target effects and immune toxicity.
Significant competition from established and emerging oncology modalities, and dependence on raising substantial capital to fund clinical development.

Competitive Landscape

Competes with other targeted delivery platforms (e.g., ligand-targeted LNPs, other nanoparticle systems) and oncology modalities like ADCs, bispecific antibodies, and cell therapies. Differentiation lies in the unique dsRNA mechanism and the claim of a modular, synthetic platform for systemic nucleic acid delivery.

More companies in Switzerland →